Genetic Deficiency of the Long Pentraxin 3 Affects Osteogenesis and Osteoclastogenesis in Homeostatic and Inflammatory Conditions.
PTX3
bone
hyaluronan-rich matrix
osteoblast
osteoclast
tissue remodeling
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
received:
20
10
2023
revised:
13
11
2023
accepted:
20
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
The long pentraxin 3 (PTX3) is a soluble glycoprotein made by immune and nonimmune cells endowed with pleiotropic functions in innate immunity, inflammation, and tissue remodeling. PTX3 has recently emerged as a mediator of bone turnover in both physiological and pathological conditions, with direct and indirect effects on osteoblasts and osteoclasts. This notwithstanding, its role in bone biology, with major regard to the osteogenic potential of osteoblasts and their interplay with osteoclasts, is at present unclear. Here, we investigated the contribution of this pentraxin to bone deposition in the osteogenic lineage by assessing collagen production, mineralization capacity, osteoblast maturation, extracellular matrix gene expression, and inflammatory mediators' production in primary osteoblasts from the calvaria of wild-type (WT) and
Identifiants
pubmed: 38068970
pii: ijms242316648
doi: 10.3390/ijms242316648
pmc: PMC10706359
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondazione Beppe e Nucci Angiolini Onlus
ID : n.a.
Références
Proc Natl Acad Sci U S A. 2022 Aug 16;119(33):e2208144119
pubmed: 35939690
Front Immunol. 2018 Mar 05;9:417
pubmed: 29556234
Bone Res. 2023 Aug 15;11(1):44
pubmed: 37580331
J Biol Chem. 1999 Aug 27;274(35):25085-92
pubmed: 10455188
Int J Mol Sci. 2021 May 31;22(11):
pubmed: 34073015
Cell Death Dis. 2017 Oct 12;8(10):e3125
pubmed: 29022895
Semin Cell Dev Biol. 2016 Jan;49:2-10
pubmed: 26481971
Nat Commun. 2018 Jul 25;9(1):2909
pubmed: 30046091
Front Immunol. 2019 Dec 13;10:2759
pubmed: 31921102
J Bone Miner Res. 2022 Jan;37(1):137-151
pubmed: 34633111
Physiol Rev. 2016 Apr;96(2):409-47
pubmed: 26842265
Bone. 2022 Jan;154:116231
pubmed: 34653679
Physiol Rev. 2018 Apr 1;98(2):623-639
pubmed: 29412047
Endocrinology. 2014 May;155(5):1589-95
pubmed: 24437492
Clin Transl Med. 2022 Jan;12(1):e724
pubmed: 35090088
J Cell Physiol. 2014 Nov;229(11):1744-52
pubmed: 24664887
Elife. 2023 May 24;12:
pubmed: 37222419
Semin Immunol. 2013 Feb;25(1):73-8
pubmed: 23768898
Front Immunol. 2019 Sep 13;10:2182
pubmed: 31572390
Int Immunol. 2021 Nov 25;33(12):673-678
pubmed: 34415037
Endocrinol Metab (Seoul). 2023 Oct;38(5):504-521
pubmed: 37749800
Front Microbiol. 2023 Apr 06;14:1124945
pubmed: 37089533
Clin Chem. 1999 Aug;45(8 Pt 2):1353-8
pubmed: 10430818
Histol Histopathol. 2001 Apr;16(2):603-11
pubmed: 11332716
J Clin Invest. 2019 Jul 15;129(8):3018-3028
pubmed: 31305265
J Cell Physiol. 2023 Jul;238(7):1431-1464
pubmed: 37183350
Front Immunol. 2022 Nov 22;13:1048505
pubmed: 36483565
Nat Rev Endocrinol. 2023 Dec;19(12):708-721
pubmed: 37715028
J Biol Chem. 2008 Apr 11;283(15):10147-61
pubmed: 18223257
FEBS Lett. 2003 Mar 27;539(1-3):45-50
pubmed: 12650924
J Clin Med. 2023 Jan 29;12(3):
pubmed: 36769703
Mol Cell Proteomics. 2016 Feb;15(2):558-72
pubmed: 26598647
Front Immunol. 2014 Feb 13;5:48
pubmed: 24592264
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32436939
Cell Biosci. 2013 Jan 15;3(1):4
pubmed: 23321200
Front Immunol. 2021 Jan 29;11:622772
pubmed: 33584725
Biomed Pharmacother. 2020 Nov;131:110628
pubmed: 32890968
Dis Markers. 2013;34(3):143-51
pubmed: 23324586
Front Immunol. 2019 Nov 08;10:2628
pubmed: 31787987
J Exp Med. 2015 Jun 1;212(6):905-25
pubmed: 25964372
Oncotarget. 2014 Jan 30;5(2):481-92
pubmed: 24457902
Front Immunol. 2023 Oct 09;14:1274634
pubmed: 37885881
Autoimmun Rev. 2020 Dec;19(12):102584
pubmed: 32534154
Biochem Biophys Res Commun. 2023 Oct 15;677:20-25
pubmed: 37542771